Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Senate Budget Draft Would Be Less Generous To US FDA Than House For FY 2023

01 Aug 2022

• By Derrick Gingery

comparing coins — The Senate offered less of an increase in FY 2023 funding for the FDA than the House of Representatives. • Source: Shutterstock

Related Content

US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews

29 Oct 2018

House ALS Bill Would Require US FDA ‘Action Plan’ – But Not Conditional Approval

16 Nov 2021

Here We Go Again: US FDA Weighing Accelerated Approval For Biogen’s ALS Drug Tofersen

27 Jul 2022

ALS Drugs: Second US FDA Meeting On AMX0035 Gives Amylyx A Chance To Capitalize On Recent Events

29 Jul 2022

US FDA User Fees: Lay-Off Notices Planned For Early September If Congress Doesn’t Pass Bill

28 Jul 2022

Aduhelm, One Year Later: US FDA’s Credibility, Accelerated Approval Pathway Feel The Bite From Alzheimer’s Drug Approval

06 Jun 2022

Rare Disease Challenges At US FDA: CDER Director Says More Staff, Not Reorganization, Will Fix Issues

06 Apr 2022

Related Companies

Biogen, Inc.

Amylyx Pharmaceuticals, Inc.

Additional Topics

United States Legislation Regulation Rare Diseases FDA User Fees Neurology BioPharmaceutical

More from Legislation

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.